InvestSMART

Truscreen Group Limited (ASX:TRU)

ALERT: Price-sensitive ASX Announcement for TRU
Current share price for TRU : $0.012 -0.005 (-29.41%)+
Announcement
Release
29 May 2026 7:30AM
Price at Release
$0.017
Full Release
download
Summary
TruScreen Group Limited, an AI-enabled cervical cancer screening company, reported over NZD 2.4 million in sales for FY2026, a 42% increase from the previous year. The company emphasizes its operations in low and middle-income countries such as Vietnam, India, and Indonesia. TruScreen has secured regulatory approvals in several countries and expanded its distributor footprint to new regions including South Africa and Uzbekistan. With a focus on rapid market access and studies validating its technology, the company's FY2027 strategy includes further regulatory approvals and geographical expansion.
Key Points
  • TruScreen Group Limited is a life science company specializing in AI-enabled real-time cervical cancer screening.
  • FY2026 sales exceeded NZD 2.4 million with a 42% year-over-year growth.
  • TruScreen focuses on markets in low and middle-income countries like China, Vietnam, India, and Indonesia.
  • The company has established regulatory approvals in multiple countries, including China, Mexico, Vietnam, and Uzbekistan.
  • TruScreen's device is a point-of-care technology that does not require lab infrastructure, making it suitable for regions with limited resources.
  • In FY2026, TruScreen expanded its distributor network to include South Africa, Uzbekistan, Bangladesh, Romania, and Italy.
  • The Vietnam program aims to screen 260,000 women over five years as part of a cervical cancer screening initiative.
  • TruScreen is involved in several notable studies and collaborations, including a landmark study with WHO and a consortium proposal with UNITAID.
  • The company has a strategic alliance with DaltonBio for HPV-related products.
  • FY2027 outlook includes regulatory approvals in India, South Africa, and expansion in Indonesia and Mexico.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.